Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Feb 13, 2018 at 1:30 PM EST

Why Catabasis Is Tuesday’s Biggest Winner

Catabasis Pharmaceuticals saw its shares skyrocket on Tuesday after the firm announced new results from its Duchene muscular dystrophy study…

Chris Lange | Feb 13, 2018 at 9:40 AM EST

BioXel Gears Up for IPO

Clinical-stage biopharmaceutical company BioXel Therapeutics has filed with the SEC regarding its initial public offering.

Chris Lange | Feb 12, 2018 at 10:20 AM EST

Is This the End of Axovant?

Axovant Sciences saw its shares take a big step back to start out the week after the company announced that…

Chris Lange | Feb 12, 2018 at 9:35 AM EST

Short Sellers Can’t Make Up Their Minds on Major Pharma

The January 31 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Feb 12, 2018 at 9:15 AM EST

Major Biotechs See Rising Tide of Short Interest

The January 31 short interest data have been compared with the previous report, and short interest in most of the…

Paul Ausick | Feb 8, 2018 at 10:00 AM EST

CVS Earnings Yield Boosts to Starting Pay, Benefits

Pharmacy retailer CVS beat estimates when it reported results Thursday morning. The company is using some of its tax windfall…

Paul Ausick | Feb 8, 2018 at 9:00 AM EST

Drugs, Alcohol, Suicide Causes of Low US Life Expectancy

White Americans are dying at higher rates from drug overdoses, alcohol, and suicide than citizens of other developed countries and…

Lee Jackson | Feb 8, 2018 at 8:15 AM EST

JPMorgan Likes Big Cap Pharmaceutical Stocks as Market Volatility Jumps

Four large-cap pharmaceutical leaders are rated Overweight at JPMorgan, and all make sense for growth accounts looking for some safety…

Chris Lange | Feb 7, 2018 at 11:10 AM EST

Why Theravance Biopharma Shares Are Soaring

Theravance Biopharma shares made a solid gain on Wednesday after the company announced a global collaboration with Janssen Biotech.

Chris Lange | Feb 6, 2018 at 1:55 PM EST

Why Allergan Continues to Slide

Though Allergan reported better than expected quarterly results before the markets opened on Tuesday, its shares retreated.

Paul Ausick | Feb 5, 2018 at 10:35 AM EST

Bristol-Myers Squibb Earnings, Trial Results Not Enough to Please Investors

Fourth-quarter and full-year earnings at Bristol-Myers Squibb beat estimates, but a report of the successful trial of the company's lung…

Chris Lange | Feb 3, 2018 at 8:50 AM EST

Major Biopharma Catalysts on February’s FDA Calendar

24/7 Wall St. has included a calendar of a some of the biggest companies expecting clinical trial and U.S. Food…

Chris Lange | Feb 2, 2018 at 9:45 AM EST

Evolus Gears Up for IPO

Medical aesthetics company Evolus expects to price 5.0 million shares in a range that results in an initial public offering…

Chris Lange | Feb 2, 2018 at 8:59 AM EST

Merck Sees Big Boost From Keytruda in Q4

Merck reported mixed fourth-quarter financial results before the markets opened on Friday.

Chris Lange | Jan 31, 2018 at 11:00 AM EST

Why Cascadian Therapeutics Shares Are Skyrocketing

Cascadian Therapeutics saw its shares absolutely skyrocket on Wednesday after it was announced that Seattle Genetics would be acquiring the…

1 … 142 143 144 145 146 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Why Catabasis Is Tuesday’s Biggest Winner

BioXel Gears Up for IPO

Is This the End of Axovant?

Short Sellers Can’t Make Up Their Minds on Major Pharma

Major Biotechs See Rising Tide of Short Interest

CVS Earnings Yield Boosts to Starting Pay, Benefits

Drugs, Alcohol, Suicide Causes of Low US Life Expectancy

JPMorgan Likes Big Cap Pharmaceutical Stocks as Market Volatility Jumps

Why Theravance Biopharma Shares Are Soaring

Why Allergan Continues to Slide

Bristol-Myers Squibb Earnings, Trial Results Not Enough to Please Investors

Major Biopharma Catalysts on February’s FDA Calendar

Evolus Gears Up for IPO

Merck Sees Big Boost From Keytruda in Q4

Why Cascadian Therapeutics Shares Are Skyrocketing

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Health and Healthcare Articles

All Health and Healthcare Articles

Why Catabasis Is Tuesday’s Biggest Winner

BioXel Gears Up for IPO

Is This the End of Axovant?

Short Sellers Can’t Make Up Their Minds on Major Pharma

Major Biotechs See Rising Tide of Short Interest

CVS Earnings Yield Boosts to Starting Pay, Benefits

Drugs, Alcohol, Suicide Causes of Low US Life Expectancy

JPMorgan Likes Big Cap Pharmaceutical Stocks as Market Volatility Jumps

Why Theravance Biopharma Shares Are Soaring

Why Allergan Continues to Slide

Bristol-Myers Squibb Earnings, Trial Results Not Enough to Please Investors

Major Biopharma Catalysts on February’s FDA Calendar

Evolus Gears Up for IPO

Merck Sees Big Boost From Keytruda in Q4

Why Cascadian Therapeutics Shares Are Skyrocketing

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how